Form 4: Bristol-Myers Squibb Director Derica W. Rice Reports Acquisition of Deferred Share Units

Director Derica W. Rice reports acquiring deferred share units convertible to common stock in Bristol-Myers Squibb.

Summary

• On September 30, 2024, Derica W. Rice, a director of Bristol-Myers Squibb, reported the acquisition of 724.778 deferred share units.
• These units are convertible into shares of common stock upon settlement, which occurs when Rice ceases to be a director or at a previously specified future date.
• The price of the derivative security is $51.74.
• Following the transaction, Rice beneficially owns 25,892.231 derivative securities, including deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a director acquiring deferred share units, which is a common form of compensation. It doesn't necessarily indicate a strong positive or negative outlook.

Positives

• The acquisition of deferred share units by a director signals confidence in the company's future performance.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which will occur when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers. These filings are closely watched by investors as they can provide insights into management's perspective on the company's stock.

Stakeholder Impact

• The acquisition of deferred share units by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates